"Late-preterm" infants: a population at risk

Pediatrics
|December 7, 2007
PubMed

Insights

Late-preterm infants born between 34 and 36 weeks gestation face higher health risks. This report advocates for "late preterm" terminology and outlines management guidelines for these vulnerable newborns.

Area of Science:

  • Neonatal Medicine
  • Perinatal Health
  • Infant Development

Background:

  • Late-preterm infants (34-36 weeks gestation) exhibit reduced physiological and metabolic maturity compared to full-term infants.
  • These infants are recognized to have a higher incidence of morbidity and mortality than their full-term counterparts.
  • Current terminology like "near term" may not adequately convey the unique risks associated with this gestational age.

Purpose of the Study:

  • To establish a clear definition for "late preterm" infants.
  • To recommend a standardized terminology, replacing "near term" with "late preterm."
  • To delineate characteristics predisposing late-preterm infants to increased health risks and propose evidence-based management guidelines.

Main Methods:

  • Literature review and synthesis of existing research on late-preterm infant outcomes.
  • Analysis of physiological and metabolic characteristics differentiating late-preterm from term infants.
  • Development of clinical guidelines based on identified risk factors and current best practices.

Main Results:

  • Late-preterm infants possess distinct developmental immaturities increasing their susceptibility to complications.
  • Specific risk factors contributing to higher morbidity and mortality rates have been identified.
  • The proposed guidelines offer a framework for consistent evaluation and management.

Conclusions:

  • Adopting the term "late preterm" improves clarity and recognition of this population's unique needs.
  • Early identification of risk factors and appropriate postnatal care are crucial for improving outcomes.
  • Standardized management protocols can mitigate the increased risks faced by late-preterm infants.

Related Concept Videos

Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...